Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer GlobeNewswire December 17, 2025 Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) — Processa […]

SharpLink Appoints Joseph Chalom as Sole CEO and Member of the Board; Rob Phythian Steps Down Following Company's Planned Transition GlobeNewswire December 17, 2025 Minneapolis, MN, Dec. 17, 2025 (GLOBE NEWSWIRE) — SharpLink Gaming, Inc. (Nasdaq: SBET) (“SharpLink” or the “Company”), one of the world's largest corporate holders of Ether (“ETH”) and prominent industry advocate

The 2026 State of Performance Marketing Report: How Inflated Signals, AI Noise, and Disconnected Tools Are Derailing B2B Growth Survey of 750 marketing leaders finds AI is amplifying performance noise while 25% of marketing spend fails to drive outcomes. GlobeNewswire December 17, 2025 DANVERS, MA, Dec. 17, 2025 (GLOBE NEWSWIRE) — Danvers, Mass., December 17,

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1) GlobeNewswire December 17, 2025 Completion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings,

SAGA Metals Defines Key Structural Geology at Trapper South & Provides Corporate Update GlobeNewswire December 17, 2025 VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) — SAGA Metals Corp. (“SAGA” or the “Company”) (TSXV: SAGA) (OTCQB: SAGMF) (FSE: 20H), a North American exploration company advancing critical mineral discoveries, is pleased to announce the full logging

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement GlobeNewswire December 17, 2025 Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor (“TSHR”) antibody for Graves' disease (“GD”) and thyroid eye disease (“TED”) Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance

Enecom, Inc., a Japanese ICT Services Provider, Enhances Its Enterprise Data Infrastructure with the InfiniBox(R) Solution for 100% Availability and Cyber Resilient Storage GlobeNewswire December 17, 2025 WALTHAM, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) — Infinidat, a leading provider of enterprise storage solutions, today announced that Enecom, Inc., an information and communication technology (ICT) services

TadHealth Awarded San Diego County Office of Education Contract; School Districts to Begin CYBHI Billing in January 2026 GlobeNewswire December 17, 2025 COSTA MESA, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) — TadHealth, a leading provider of school-based mental health technology, has been selected by the San Diego County Office of Education (SDCOE) to deliver a

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D GlobeNewswire December 17, 2025 Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support

Asia Broadband Corporate Update and Projects Status Scheduled For January 2026 and AABB Shareholders Merry Christmas GlobeNewswire December 17, 2025 LAS VEGAS, Dec. 17, 2025 (GLOBE NEWSWIRE) — Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that the Company is set to release a corporate update in January 2026. After